Mechanisms of host defense against infection with Streptococcus pneumoniae

Clinical Infectious Diseases

Volumn 14, Issue 1, 1992, Pages 251-262

  Bruyn, G A W ^b   Zegers, B J M ^b   Van Furth, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; HUMAN; IMMUNOLOGY; MICROBIOLOGY; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; ULTRASTRUCTURE; BACTERIAL INFECTION; CELL MEMBRANE; CELL WALL; CELLULAR IMMUNITY; ENCAPSULATION; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNOGENICITY; PATHOGENICITY; PRIORITY JOURNAL; SEROTYPE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; HUMAN; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

COMPLEMENT; IMMUNOGLOBULIN CLASS; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

EID: 0026611642     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/14.1.251     Document Type: Review

References (141)

1. Bezançon F, Griffon V. Pouvoir agglutinatif du sérum dans les infections expérimentales et humaines à pneumocoques. C R Soc Biol (Paris) 1897;iv:551-3.
2. Neufeld F, Haendel L. Ueber die Entstehung der Krisis bei der Pneumonie und über die Wirkung des Pneumokokkenimmunserums. Arbeiten aus dem Kaiserlichen Gesundheitsamte 1910;34:166-81.
3. Dochez AR, Gillespie LJ. A biologic classification of pneumococci by means of immunity reactions. JAMA 1913;61:727-30.
4. Lister FS. Specific serological reactions with pneumococci from different sources. Public South African Institute for Medical Research 1913;1:1-14.
5. Cooper G, Rosenstein C, Walter A, Peizer L. The further separation of types among the pneumococci hitherto included in group IV and the development of the therapeutic antisera for these types. J Exp Med 1932;55:531-54.
6. Heidelberger M, Avery OT. The soluble specific substance of pneumococcus. J Exp Med 1923;38:73-9.
7. Heidelberger M, Goebel WF, Avery OT. The soluble specific substance of pneumococcus. Third paper. J Exp Med 1925;42:727-45.
8. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med 1931;54:437-47.
9. Schiemann O, Casper W. Sind die spezifisch präcipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z Hyg Infektionskr 1927;108:220-57.
10. Francis T Jr, Tillett WS. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 1930;52:573-85.
11. Finland M, Ruegsegger JM. Immunization of human subjects with the specific carbohydrates of type III and the related type VIII pneumococcus. J Clin Invest 1935;14:829-32.
12. Finland M, Sutliff WD. Specific antibody response of human subjects to intracutaneous injection of pneumococcus products. J Exp Med 1932;55:853-65.
13. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press, 1979.
14. Heidelberger M, MacLeod CM, Kaiser SJ, Robinson B. Antibody formation in volunteers following injection of pneumococci or their type-specific polysaccharides. J Exp Med 1946;83:303-20.
15. Heidelberger M, MacLeod CM, Di Lapi MM. The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J Exp Med 1948;88:369-72.
16. Heidelberger M, Di Lapi MM, Siegel M, Walter AW. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol 1950;65:535-41.
17. How MJ, Brimacombe JS, Stacey M. The pneumococcal polysaccharides. In: Wolfrom ML, ed. Advances in carbohydrate chemistry. Vol 19. New York: Academic Press, 1964:303-58.
18. Tomasz A. Surface components of Streptococcus pneumonias. Rev Infect Dis 1981;3:190-211.
19. Austrian R. Random gleanings from a life with the pneumococcus. J Infect Dis 1975;131:474-84.
20. Austrian R. Pneumococcus: the first one hundred years. Rev Infect Dis 1981;3:183-9.
21. McCarty M. Pneumococci. In: Davis BD, Dulbecco R, Eisen HN, Ginsburg HS, Wood WB, McCarty MM, eds. Microbiology. 2nd ed. Philadelphia: JB Lippincott, 1973:694-706.
22. Austrian R, MacLeod CM. A type-specific protein from pneumococcus. J Exp Med 1949;89:439-50.
23. Briles DE, Yother J, McDaniel LS. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis 1988;10(suppl):S372-4.
24. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med 1931;54:73-89.
25. Giebink GS, Verhoef J, Peterson PK, Quie PG. Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV. Infect Immun 1977;18:291-7.
26. Fine DP. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun 1975;12:772-8.
27. Hostetter MK. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis 1986; 153:682-93.
28. Knecht JC, Schiffman G, Austrian R. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. J Exp Med 1970;132:475-87.
29. White B. The biology of pneumococcus. Cambridge, MA: Harvard University Press, 1979:93, 179-210, 357-61, 698-712.
30. Van Dam JEG. Contribution to the development of a semi-synthetic vaccine to Streptococcus pneumoniae [dissertation]. Utrecht, The Netherlands: University of Ulrecht, 1988.
31. Allen PZ, Bowen WH. Immunochemical studies on pneumococcal type 37 capsular polysaccharide. Mol Immunol 1988;25:1011-7.
32. Kenne L, Lindberg B. The structure of the Streptococcus pneumoniae type 29 polysaccharide: a reexamination. Carbohydr Res 1988;184:288-91.
33. Jones C, Currie F. The pneumococcal polysaccharide S4: a structural re-assessment. Carbohydr Res 1988;184:279-84.
34. Kabat EA. The nature of an antigenic determinant. J Immunol 1966;97:1-11.
35. Wessels MR, Kasper DL. Antibody recognition of the type 14 pneumococcal capsule: evidence for a conformational epitope in a neutral polysaccharide. J Exp Med 1989;169:2121-31.
36. Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins. XII. The immunological properties of an artificial antigen containing cellobiuronic acid. J Exp Med 1938;68:469-84.
37. Heidelberger M, Jann K, Jann B, Ørskov F, Ørskov I, Westphal O. Relations between structures of three K polysaccharides of Escherichia coli and cross-reactivity in antipneumococcal sera. J Bacteriol 1968;95:2415-7.
38. Heidelberger M, Nimmich W, Eriksen J, Stirm S. Immunochemical relationships between bacteria belonging to two separate families: pneumococci and Klebsiella. Immunochemistry 1976;13:67-80.
39. Sørensen UBS, Henrichsen J. Cross-reactions between pneumococci and other streptococci due to C polysaccharide and F antigen. J Clin Microbiol 1987;25:1854-9.
40. Gwaltney JM Jr, Sande MA, Austrian R, Hendley JO. Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J Infect Dis 1975;132:62-8.
41. Neufeld F. Ueber die Agglutination der Pneumokokken und über die Theorieen der Agglutination. Z Hyg Infektionskr 1902;40:54-72.
42. Lund E, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumonias. In: Bergan T, Morris JR, eds. Methods in microbiology. Vol 12. New York: Academic Press, 1978:241-62.
43. Kauffmann F, Lund E, Eddy BE. Proposal for a change in the nomenclature of Diplococcus pneumoniae and a comparison of the Danish and American type designations. International Bulletin of Bacteriological Nomenclature and Taxonomy 1960;1:31-40.
44. Mulder J. Types of pneumococci in pneumococcal infections of adults in Holland. Acta Med Scand 1942;112:103-10.
45. Finland M, Barnes MW. Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol 1977;5:154-66.
46. Greenwood BM, Hassan-King M, Onyemelukwe G, et al. Pneumococcal serotypes in West Africa [letter]. Lancet 1980;1:360.
47. Henrichsen J. The pneumococcal typing system and pneumococcal surveillance. J Infect 1979;1(suppl 2):31-7.
48. Robbins JB, Austrian R, Lee C-J, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148:1136-59.
49. Bol P. Epidemiology of bacterial meningitis in the Netherlands [dissertation]. Amsterdam: University of Amsterdam, 1987.
50. Broome CV, Facklam RR, Allen JR, Fraser DW, Austrian R. Epidemiology of pneumococcal serotypes in the United States, 1978-1979. J Infect Dis 1980;141:119-23.
51. Lee C-J. Bacterial capsular polysaccharides - biochemistry, immunity and vaccine. Mol Immunol 1987;24:1005-19.
52. Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis 1985;151:535-40.
53. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, Hoffmann MK, Tuomanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun 1989;57:1890-3.
54. Tillett WS, Goebel WF, Avery OT. Chemical and immunological properties of a species-specific carbohydrate of pneumococci. J Exp Med 1930;52:895-900.
55. Schiffman G, Bornstein DL, Austrian R. Capsulation of pneumococcus with soluble cell wall-like polysaccharide. II. Nonidentity of cell wall and soluble cell wall-like polysaccharides derived from the same and from different pneumococcal strains. J Exp Med 1971;134:600-17.
56. Sørensen UBS, Blom J, Birch-Andersen A, Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun 1988; 56:1890-6.
57. Gotschlich EC, Liu TY. Structural and immunological studies on the pneumococcal C polysaccharide. J Biol Chem 1967;242:463-70.
58. Leon MA, Young NM. Specificity for phosphorylcholine of six murine myeloma proteins reactive with Pneumococcus C polysaccharide and β-lipoprotein. Biochemistry 1971;10:1424-9.
59. Höltje JV, Tomasz A. Purification of the pneumococcal N-acetylmuramyl-L-alanine amidase to biochemical homogeneity. J Biol Chem 1976;251:4199-207.
60. Garcia-Bustos J, Tomasz A. Mechanism of pneumococcal cell wall degradation in vitro and in vivo. J Bacteriol 1989;171:114-9.
61. Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985;151:859-68.
62. Täuber MG, Burroughs M, Niemöller UM, Kuster H, Borschberg U, Tuomanen E. Differences of pathophysiology in experimental meningitis caused by three strains of Streptococcus pneumonia?. J Infect Dis 1991;163:806-11.
63. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanism of endotoxin resistance. Science 1986;232:977-80.
64. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319:964-71.
65. Odio CM, Faingezicht I, Pazis M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324:1525-32.
66. Steinfort C, Wilson R, Mitchell T, et al. Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Infect Immun 1989;57:2006-13.
67. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989;57:2037-42.
68. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human compliment by the pneumococcal toxin pneumolysin. Infect Immun 1984;43:1085-7.
69. Berry AM, Lock RA, Hansman D, Paton JC. Contribution of autolysin to virulence of Streptococcus pneumonias. Infect Immun 1989;57:2324-30.
70. Johnston RB Jr. The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis of tissue damage. Rev Infect Dis 1981;3:282-8.
71. Guckian JC, Christensen GD, Fine DP. The role of opsonins in recovery from experimental pneumococcal pneumonia. J Infect Dis 1980;142:175-90.
72. Winkelstein JA. The role of complement in the host's defense against Streptococcus pneumoniae. Rev Infect Dis 1981;3:289-98.
73. Frank MM. Current concepts: complement in the pathophysiology of human disease. N Engl J Med 1987;316:1525-30.
74. Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol 1984;2:461-91.
75. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981;3(Suppl):S1-17.
76. Brown EJ, Hosea SW, Frank MM. The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. J Immunol 1981; 126:2230-5.
77. Brown EJ, Hosea SW, Hammer CH, Burch CG, Frank MM. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest 1982;69:85-98.
78. Hiemstra PS, Biewenga J, Gorter A, et al. Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol 1988;25:527-33.
79. 2 release by human polymorphonuclear leukocytes. Immunology 1989;67:120-5.
80. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-65.
81. Cummins L, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol 1988;140:3793-800.
82. Briles DE, Forman Horowitz JC, Volanakis JE, et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 1989;57:1457-64.
83. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 1971;136:612-4.
84. Horowitz J, Volanakis JE, Briles DE. Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol 1987;138:2598-603.
85. Perlmutter RM, Hansburg D, Briles DE, Nicolotti RA, Davie JM. Subclass restriction of murine anti-carbohydrate antibodies. J Immunol 1978;121:566-72.
86. Briles DE, Claflin JL, Schroer K, Forman C. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 1981;294:88-90.
87. Szu SC, Clarke S, Robbins JB. Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun 1983;39:993-9.
88. Au CC, Eisenstein TK. Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumococcal subcellular preparations. Infect Immun 1981;31:169-73.
89. Szu SC, Schneerson R, Robbins JB. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun 1986;54:448-55.
90. Brown EJ, Joiner KA, Cole RM, Berger M. Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun 1983;39:403-9.
91. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-56.
92. Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis 1990;161:736-40.
93. Wara DW. Host defense against Streptococcus pneumoniae: the role of the spleen. Rev Infect Dis 1981;3:299-309.
94. Coleman CN, McDougall IR, Dailey MO, Ager P, Bush S, Kaplan HS. Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Intern Med 1982;96:44-7.
95. Rogers DE. Host mechanisms which act to remove bacteria from the blood stream. Bacteriol Rev 1960;24:50-66.
96. Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981;304:245-50.
97. Friedman RL, Moon RJ. Role of Kupffer cells, complement and specific antibody in the bactericidal activities of perfused livers. Infect Immun 1980;29:152-7.
98. Brown EJ, Hosea SW, Frank MM. The role of the spleen in experimental pneumococcal bacteremia. J Clin Invest 1981;67:975-82.
99. Dickerman JD. Bacterial infection and the asplenic host: a review. J Trauma 1976;16:662-8.
100. Oldfield S, Jenkins S, Yeoman H, Gray D, McLennan ICM. Class and subclass anti-pneumococcal antibody responses in splenectomized patients. Clin Exp Immunol 1985;61:664-73.
101. Giebink GS, Foker JE, Kim Y, Schiffman G. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 1980;141:404-12.
102. Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 1977;297:897-910.
103. Aaberge IS, Michaelsen TE, Heier HE. IgG subclass antibody responses to pneumococcal polysaccharide vaccine in splenectomized, otherwise normal, individuals. Scand J Immunol 1990;31:711-6.
104. Slack J, Der-balian GP, Nahm M, Davis JM. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med 1980;151:853-62.
105. Riesen WF, Skvaril F, Braun DG. Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies. Scand J Immunol 1976;5:383-90.
106. Yount WJ, Dorner MM, Kunkel HG, Kabat EA. Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J Exp Med 1968;127:633-46.
107. Sarvas H, Rautonen N, Sipinen S, Mäkelä O. IgG subclasses of pneumococcal antibodies-effect of allotype G2m(n). Scand J Immunol 1989;29:229-37.
108. Chudwin DS, Artrip SG, Schiffman G. Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. Clin Immunol Immunopathol 1987;44:114-21.
109. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990;75:1583-6.
110. Freijd A, Hammarstrom L, Persson MAA, Smith CIE. Plasma antipneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin Exp Immunol 1984;56:233-8.
111. Rijkers G, Kuis W, de Graeff-Meeder E, Peeters CCAM, Zegers BJM. Impaired immune response to polysaccharides [letter]. N Engl J Med 1987;317:838.
112. Mond JJ. Use of the T lymphocyte regulated type 2 antigens for the analysis of responsiveness of Lyb5+ and Lyb5- B lymphocytes to T lymphocyte derived factors. Immunol Rev 1982;64:99-115.
113. Beuvery EC, Van Rossum F, Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun 1982;37:15-22.
114. Baker PJ, Stashak PW, Amsbaugh DF, Prescott B. Regulation of the antibody response to type III pneumococcal polysaccharide. IV. Role of suppressor T cells in the development of low-dose paralysis. J Immunol 1974;112:2020-7.
115. Baker PJ, Amsbaugh DF, Stashak PW, Caldes G, Prescott B. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev Infect Dis 1981;3:332-41.
116. Taylor CE, Bright R. T-cell modulation of the antibody response to bacterial polysaccharide antigens. Infect Immun 1989;57:180-5.
117. Milligan GN, Braley-Mullen H. Regulation of IgG responses by helper and suppressor T cells activated by pneumococcal capsular polysaccharides. Cell Immunol 1989;119:222-32.
118. Tvede N, Heilmann C, Christensen LD. Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides. Clin Exp Immunol 1989;76:404-11.
119. Griffoen AW, Rykers GT, Toebes EAH, Zegers BJM. The human in vitro anti-type 4 pneumococcal polysaccharide antibody response is regulated by suppressor T cells. Scand J Immunol 1991;34:229-36.
120. Caulfield MJ, Shaffer D. Immunoregulation by antigen/antibody complexes. I. Specific immunosuppression induced in vivo with immune complexes formed in antibody excess. J Immunol 1987;138:3680-3.
121. Pandey JP, Fudenberg HH, Virella G, et al. Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and meningococcus polysaccharides. Lancet 1979; 1:190-2.
122. Granoff DM, Suarez BK, Pandey JP, Shackelford PG. Genes associated with the G2m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 1988;157:1142-9.
123. Pandey JP, Baker CJ, Kasper DL, Fudenberg HH. Two unlinked genetic loci interact to control the human immune response to type III group B streptococcal antigen. J Immunogenet 1984;11:159-63.
124. Cowan MJ, Ammann AJ, Wara DW, et al. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978;62:721-7.
125. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-7.
126. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76.
127. Ambrosino DM, Siber GR, Chilmonczyk BA, Jernberg JB, Finberg RW. An immunodeficiency characterized by impaired antibody responses to polysaccharides. N Engl J Med 1987;316:790-3.
128. Rijkers GT, Dollekamp EG, Zegers BJM. The in vitro B-cell response to pneumococcal polysaccharides in adults and neonates. Scand J Immunol 1987;25:447-52.
129. Fattom A, Vann WF, Szu SC, et al. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun 1988;56:2292-8.
130. Lee C-J, Lin K-T. Studies on vaccine control and immunogenicity of polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 1981;3(suppl):S51-9.
131. Schneerson R, Robbins JB, Chu C, et al. Serum antibody responses of juvenile and infant Rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 1984;45:582-91.
132. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influence type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987;317:717-22.
133. Stats D, Bullowa JGM. Failure of the human convalescent type-specific antipneumococcic antibody to fix complement. J Immunol 1942;44:41-7.
134. Hosea S, Burch C, Brown E, Fletcher W, Hammer C, Frank MM. Relative contributions of antibody and complement in opsonization of the pneumococcus after immunization with the polyvalent pneumococcal vaccine [abstract]. Clin Res 1981;29:387.
135. Winkelstein JA, Shin HS, Wood WB Jr. Heat labile opsonins to pneumococcus. III. The participation of immunoglobulin and of the alternative pathway of C3 activation. J Immunol 1972;108:1681-9.
136. Joiner KA. Complement evasion by bacteria and parasites. Annu Rev Microbiol 1988;42:201-30.
137. Winkelstein JA, Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol 1978;120:174-8.
138. Brown EJ, Joiner KA, Gaither TA, Hammer CA, Frank MM. The interaction of C3b bound to pneumococci with factor H (β1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. J Immunol 1983;131:409-15.
139. Winkelstein JA, Abramowitz AS, Tomasz A. Activation of C3 via the alternative pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol 1976;116:367-70.
140. Reed WP, Davidson MS, Williams RC Jr. Complement system in pneumococcal infections. Infect Immun 1976;13:1120-5.
141. Perrin LH, Lambert PH, Nydegger UE, Miescher PA. Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level. Clin Immunol Immunopathol 1973;2:16-27.